BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Datasea Lists NeuroVibe Biofeedback System with US FDA as Class II 510(k)-Exempt Device

Datasea Intelligent Technology Ltd. (NASDAQ: DTSS) ("Datasea" or the "Company"), a technology company focused on acoustic high-tech and AI multimodal digit...

August 13, 2026 | News

Kodiak Sciences Enrols First Patients in Phase III ALTO Trial of KSI-501 for Diabetic Macular Edema

Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializin...

August 12, 2026 | News

HanchorBio Partners with Taiwan Cancer Moonshot Team to Advance Precision Immunotherapy

Collaboration connects internationally recognized cancer multi-omics research with HanchorBio's clinical-stage immuno-oncology platform to accelerate bioma...

August 11, 2026 | News

RiboX Secures FDA IND Clearance for World’s First Circular RNA-Based In Vivo CAR-T Therapy

The FDA IND clearance supports the initiation of RiboX's Phase 1 clinical trial evaluating targeted LNP-delivered circular RNA-based in vivo CAR-T therapy ...

August 10, 2026 | News

Alteogen Signs Up to $365 Million Hybrozyme Licensing Deal for Subcutaneous Biologic

Alteogen grants exclusive rights to develop and commercialize a subcutaneous biologic product using Hybrozyme™-based hyaluronidase ALT-B4 Alteogen...

August 07, 2026 | News

Forlong Biotechnology Completes Pivotal FL115 Manufacturing Milestone Ahead of Phase III NMIBC Trial

Forlong Biotechnology, a clinical-stage biotech company focused on developing transformative cytokine therapies for patients with severe unmet needs, today...

August 06, 2026 | News

Vaxcellbio Partners with Myellama to Advance Next-Generation NK Cell Therapy for Multiple Myeloma

Vaxcellbio (CEO Je-Jung Lee, MD, PhD), a leading immuno-oncology company, announced today that it has signed a strategic Memorandum of Understanding ...

August 05, 2026 | News

From Market Access to Long-Term Growth: Rethinking Biopharma Expansion in APAC

BioPharma APAC speaks with Girisan Kariangal, Regional Vice President – Business Development & Alliance Management, Menarini Asia-Pacific, on the...

August 04, 2026 | Interaction

8 APAC Assets That Went Global The Out-Licensing Class of 2025 to 2026

Business development teams across the region keep arriving at the same question, phrased slightly differently each time. What did a comparable asset, at a ...

July 29, 2026 | Analysis

AsymBio Breaks Ground on Shanghai R&D Hub to Accelerate Biologics Development

AsymBio, a biologics-focused Contract Development and Manufacturing Organization (CDMO) and a subsidiary of Asymchem Group (stock codes: 002821.S...

July 29, 2026 | News

AnHorn Medicines Advances First-in-Class AH-008 into Phase I Trial for Chemotherapy-Induced Neuropathy Prevention

AnHorn Medicines announced the successful completion of the first subject first dose in the Phase I clinical trial of AH-008, a first-in-class neuroprotect...

July 27, 2026 | News

ArkBio Completes Dosing in Phase I Trial of Long-Acting Influenza Prevention Candidate AK0406

Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that all cohorts of healthy volunteers have been dosed in an Australian Phase I trial w...

July 27, 2026 | News

Ribo’s Vortosiran Achieves 92% FXI Activity Reduction in Phase 2a Coronary Artery Disease Study

Suzhou Ribo Life Science Co., Ltd. (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo") today announce at C...

July 24, 2026 | News

Tikva Allocell Raises $8M Series A to Advance Off-the-Shelf CAR-T Therapy for Solid Tumours

Funding will support completion of IND-enabling activities and planned year-end IND submission for TAVST01, Tikva's lead off-the-shelf CAR-T candidate targ...

July 24, 2026 | News

Stay Connected